Vortrag
Synthetic macrocyclic peptides that target protein-protein interactions: the discovery and early chemistry development of a PCSK9 inhibitor
Veranstaltungen
23.02.22
16:00 – 17:00
Medizinische Chemie
Dies ist ein Online Event
Dr. David Thaisrivongs
MSD
Inhibition of Proprotein Convertase Subtilisin/Kexin type-9 (PCSK9) improves cardiovascular outcomes in patients requiring additional low-density lipoprotein cholesterol reduction on top of statins, but there has been limited uptake of the two commercialized PCSK9 antibody inhibitors due in part to cost and route of administration. The protein-protein interaction between PCSK9 and the low-density lipoprotein receptor which is targeted by these therapies is a large, flat surface, which has made the discovery of orally-bioavailable small molecule inhibitors highly challenging. This talk will introduce the use of macrocyclic peptides to interrupt such protein-protein interactions, and describe the discovery and early chemistry development of such a PCSK9 inhibitor.
Kontaktperson
Alexander Lorey
Zu Ihrem Kalender hinzufügen
In andere Kalender herunterladen
Interessen
Medizinische Chemie
Veranstaltungsdetails
23.02.22
16:00 – 17:00
Medizinische Chemie
Dies ist ein Online Event
Dr. David Thaisrivongs
MSD
Kontaktperson
Alexander Lorey
Zu Ihrem Kalender hinzufügen
In andere Kalender herunterladen
